Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0U4JD
|
|||
| Former ID |
DNC013326
|
|||
| Drug Name |
(S)-N2-[4-(benzyloxy)benzyl]serinamide
|
|||
| Synonyms |
CHEMBL243058; (S)-N2-[4-(benzyloxy)benzyl]serinamide; SCHEMBL7394895; ZINC28711471
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H20N2O3
|
|||
| Canonical SMILES |
C1=CC=C(C=C1)COC2=CC=C(C=C2)CNC(CO)C(=O)N
|
|||
| InChI |
1S/C17H20N2O3/c18-17(21)16(11-20)19-10-13-6-8-15(9-7-13)22-12-14-4-2-1-3-5-14/h1-9,16,19-20H,10-12H2,(H2,18,21)/t16-/m0/s1
|
|||
| InChIKey |
JMIJOQDPXHRPOI-INIZCTEOSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Monoamine oxidase type B (MAO-B) | Target Info | Inhibitor | [1] |
| BioCyc | Superpathway of tryptophan utilization | |||
| Tryptophan degradation via tryptamine | ||||
| Dopamine degradation | ||||
| Putrescine degradation III | ||||
| Noradrenaline and adrenaline degradation | ||||
| KEGG Pathway | Glycine, serine and threonine metabolism | |||
| Arginine and proline metabolism | ||||
| Histidine metabolism | ||||
| Tyrosine metabolism | ||||
| Phenylalanine metabolism | ||||
| Tryptophan metabolism | ||||
| Drug metabolism - cytochrome P450 | ||||
| Metabolic pathways | ||||
| Serotonergic synapse | ||||
| Dopaminergic synapse | ||||
| Cocaine addiction | ||||
| Amphetamine addiction | ||||
| Alcoholism | ||||
| Panther Pathway | Adrenaline and noradrenaline biosynthesis | |||
| 5-Hydroxytryptamine degredation | ||||
| Dopamine receptor mediated signaling pathway | ||||
| Pathway Interaction Database | Alpha-synuclein signaling | |||
| WikiPathways | Tryptophan metabolism | |||
| Dopamine metabolism | ||||
| Phase 1 - Functionalization of compounds | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoa... J Med Chem. 2007 Oct 4;50(20):4909-16. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.